title: Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
abstract: Breast cancer is a heterogeneous disease that encompasses a wide range of histopathological types including: invasive ductal carcinoma, lobular carcinoma, medullary carcinoma, mucinous carcinoma, tubular carcinoma, and apocrine carcinoma among others. Pure apocrine carcinomas represent about 0.5% of all invasive breast cancers according to the Danish Breast Cancer Cooperative Group Registry, and despite the fact that they are morphologically distinct from other breast lesions, there are at present no standard molecular criteria available for their diagnosis. In addition, the relationship between benign apocrine changes and breast carcinoma is unclear and has been a matter of discussion for many years. Recent proteome expression profiling studies of breast apocrine macrocysts, normal breast tissue, and breast tumours have identified specific apocrine biomarkers [15-hydroxyprostaglandin dehydrogenase (15-PGDH) and hydroxymethylglutaryl coenzyme A reductase (HMG-CoA reductase)] present in early and advanced apocrine lesions. These biomarkers in combination with proteins found to be characteristically upregulated in pure apocrine carcinomas (psoriasin, S100A9, and p53) provide a protein expression signature distinctive for benign apocrine metaplasias and apocrine cystic lesions. These studies have also presented compelling evidence for a direct link, through the expression of the prostaglandin degrading enzyme 15-PGDH, between early apocrine lesions and pure apocrine carcinomas. Moreover, specific antibodies against the components of the expression signature have identified precursor lesions in the linear histological progression to apocrine carcinoma. Finally, the identification of proteins that characterize the early stages of mammary apocrine differentiation such as 15-PGDH, HMG-CoA reductase, and cyclooxygenase 2 (COX-2) has opened a window of opportunity for pharmacological intervention, not only in a therapeutic manner but also in a chemopreventive setting. Here we review published and recent results in the context of the current state of research on breast apocrine cancer.
authors.affiliation: Danish Centre for Translational Breast Cancer Research (DCTB), Strandboulevarden 49, DK-2100, Copenhagen, Denmark. jec@cancer.dk
authors.forename: Julio E
authors.initials: JE
authors.lastname: Celis
authors.forename: Irina
authors.initials: I
authors.lastname: Gromova
authors.forename: Pavel
authors.initials: P
authors.lastname: Gromov
authors.forename: José M A
authors.initials: JM
authors.lastname: Moreira
authors.forename: Teresa
authors.initials: T
authors.lastname: Cabezón
authors.forename: Esbern
authors.initials: E
authors.lastname: Friis
authors.forename: Fritz
authors.initials: F
authors.lastname: Rank
mesh_terms: D001050:Apocrine Glands / Q000378:metabolism / Q000473:pathology*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D009363:Neoplasm Proteins / Q000378:metabolism*
chemical_list: D009363:Neoplasm Proteins